The Dutch childhood oncology group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2191-2198

  Sieswerda, E ^a   Postma, A ^b   van Dalen, E C ^a   van der Pal, H J H ^a,c   Tissing, W J E ^b   Rammeloo, L A J ^d   Kok, W E M ^c   van Leeuwen, F E ^e   Caron, H N ^a   Kremer, L C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cardiotoxicity; Childhood cancer survivors; Clinical practice guideline

Indexed keywords

ARTICLE; CANCER SURVIVOR; CARDIOTOXICITY; CHILDHOOD CANCER; ECHOCARDIOGRAPHY; FOLLOW UP; HEART DISEASE; HIGH RISK PATIENT; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SCREENING;

CHILD; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HUMANS; NEOPLASMS; SURVIVORS;

EID: 84864915822     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr595     Document Type: Article

References (57)

1. Geenen MM, Cardous-Ubbink MC, Kremer LC et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007; 297: 2705-2715.
2. Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-1582.
3. Bhatia S, Meadows AT. Long-term follow-up of childhood cancer survivors: future directions for clinical care and research. Pediatr Blood Cancer 2006; 46: 143-148.
4. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54: 208-236.
5. Skinner R, Wallace WH, Levitt GA. Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol 2006; 7: 489-498.
6. Armstrong GT, Liu Q, Yasui Y et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338.
7. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
8. van der Pal HJ, van Dalen EC, Kremer LC et al. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev 2005; 31: 173-185.
9. Kremer LC, van der Pal HJ, Offringa M et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13: 819-829.
10. Kremer LC, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002; 13: 503-512.
11. Mulrooney DA, Yeazel MW, Kawashima T et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606.
12. van Dalen EC, van der Pal HJ, Kok WE et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006; 42: 3191-3198.
13. van der Pal HJ, van Dalen EC, Hauptmann M et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010; 170: 1247-1255.
14. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers, Version 3.0 Arcadia, CA. October 2006. www.survivorshipguidelines.org (10 April 2011, date last accessed).
15. Scottish Intercollegiate Guidelines Network (SIGN). Long-Term Follow Up Care of Survivors of Childhood Cancer 2004: Guideline no. 76. www.sign.ac.uk/pdf/sign76.pdf (10 April 2011, date last accessed).
16. United Kingdom Children's Cancer Study Group LEG2. Therapy Based Long Term Follow Up: A Practice Statement, 2nd edition. www.ukccsg.org (10 April 2011, date last accessed).
17. Schwartz CL, Hobbie WL, Constine LS et al. Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach 2005Berlin, GermanySpringer.
18. Wallace WH, Green DM. Late Effects of Childhood Cancer 2004LondonArnold.
19. Lundh A, Knijnenburg SL, Jorgensen AW et al. Quality of systematic reviews in pediatric oncology-a systematic review. Cancer Treat Rev 2009; 35: 645-652.
20. Burgers JS, van Everdingen JJ. [Evidence-based guideline development in the Netherlands: the EBRO platform]. Ned Tijdschr Geneeskd 2004; 148: 2057-2059.
21. Pein F, Sakiroglu O, Dahan M et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004; 91: 37-44.
22. Green DM, Grigoriev YA, Nan B et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19: 1926-1934.
23. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-3148.
24. van Dalen EC, van der Pal HJ, Bakker PJ et al. Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004; 40: 643-652.
25. Sorensen K, Levitt GA, Bull C et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97: 1991-1998.
26. Hudson MM, Rai SN, Nunez C et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25: 3635-3643.
27. Lipshultz SE, Lipsitz SR, Mone SM et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743.
28. Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-2636.
29. Schellong G, Riepenhausen M, Bruch C et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55: 1145-1152.
30. van Dalen EC, van der Pal HJ, van den Bos C et al. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer 2006; 42: 2549-2553.
31. Bar J, Davidi O, Goshen Y et al. Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 2003; 189: 853-857.
32. Brouwer CA, Gietema JA, van den Berg MP et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 2006; 17: 1586-1591.
33. Poutanen T, Tikanoja T, Riikonen P et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003; 21: 2349-2356.
34. Bryant J, Picot J, Baxter L et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007; 43: 1959-1966.
35. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-691.
36. Giannuzzi P, Temporelli PL, Bosimini E et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-390.
37. Jong P, Yusuf S, Rousseau MF et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-1848.
38. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-1676.
39. Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 1992; 70: 1180-1184.
40. Lewis EF, Moye LA, Rouleau JL et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003; 42: 1446-1453.
41. McDonagh TA, Cunningham AD, Morrison CE et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86: 21-26.
42. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
43. Wang TJ, Evans JC, Benjamin EJ et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108: 977-982.
44. Silber JH, Cnaan A, Clark BJ et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-828.
45. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
46. Exner DV, Dries DL, Waclawiw MA et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33: 916-923.
47. Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of betablockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29: 229-236.
48. Davis LE, Brown CE. Peripartum heart failure in a patient treated previously with doxorubicin. Obstet Gynecol 1988; 71: 506-508.
49. Katz A, Goldenberg I, Maoz C et al. Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin. Am J Med Sci 1997; 314: 399-400.
50. Ren X, Ristow B, Na B et al. Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 2007; 99: 1643-1647.
51. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 2004; 90: 1214-1216.
52. van Royen N, Jaffe CC, Krumholz HM et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996; 77: 843-850.
53. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008; 38: 101-113.
54. Hill SA, Balion CM, Santaguida P et al. Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. Clin Biochem 2008; 41: 240-249.
55. SKION LATER. Richtlijn follow-up na kinderkanker-meer dan 5 jaar na diagnose. Aanbevelingen 16-03-2010. Den Haag/Amsterdam, The NetherlandsSKION 2011.
56. Shankar SM, Marina N, Hudson MM et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008; 121: e387-e396.
57. West SG, Duan N, Pequegnat W et al. Alternatives to the randomized controlled trial. Am J Public Health 2008; 98: 1359-1366.